Better Buy: CRISPR Therapeutics vs. Vertex Pharmaceuticals [The Motley Fool]
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: The Motley Fool
Better Buy: CRISPR Therapeutics vs. Vertex Pharmaceuticals The U.S. Food and Drug Administration recently granted fast-track status to the first experimental new therapy from CRISPR Therapeutics ( NASDAQ:CRSP Vertex Pharmaceuticals NASDAQ:VRTX Both of these companies stand to earn a great deal if their one-time cure for blood-based disorders performs as well as hoped. Let's compare the different challenges and opportunities ahead of these biotechs to see which is the better stock to buy at the moment. Image source: Getty Images. The case for CRISPR Therapeutics If the name didn't tip you off, CRISPR Therapeutics is trying to develop new treatments that use Cas9, an enzyme bacteria used to fight viral infections, to edit DNA at precise locations called clustered regularly interspaced short palindromic repeats (CRISPR). This biotech's first new drug candidate to begin human trials, CTX00, is aimed at two blood-based disorders with the same problem. Patients who inherit sickle cell disea
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- CRISPR and Cas Gene Market to Grow at CAGR of 17.31% through 2033 - Rising Prevalence of Genetic Disorders & Diseases to Bolster Growth [Yahoo! Finance]Yahoo! Finance
- Vertex tops Q1 profit estimates on robust demand for cystic fibrosis treatments [Yahoo! Finance]Yahoo! Finance
- CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards? [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics AG (CRSP) Outperforms Broader Market: What You Need to Know [Yahoo! Finance]Yahoo! Finance
- Crispr Therapeutics: Market Misunderstanding Is Your Buying Opportunity (Upgrade) [Seeking Alpha]Seeking Alpha
CRSP
Earnings
- 2/21/24 - Beat
CRSP
Sec Filings
- 4/17/24 - Form 4
- 4/15/24 - Form 144
- 4/10/24 - Form SC
- CRSP's page on the SEC website